NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NPCE NeuroPace Inc.

Market Closed 07-24 16:00:00 EDT

14.81

+0.13

+0.89%

盘后14.81

+0.000.00%

19:34 EDT

High15.00	Low14.28	Vol268.93K
Open14.87	D1 Closing14.68	Amplitude4.90%
Mkt Cap504.93M	Tradable Cap344.79M	Total Shares34.09M
T/O3.95M	T/O Rate1.16%	Tradable Shares23.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NPCE","market":"US","secType":"STK","nameCN":"NeuroPace Inc.","latestPrice":14.81,"timestamp":1784923200000,"preClose":14.68,"halted":0,"volume":268928,"hourTrading":{"tag":"盘后","latestPrice":14.81,"preClose":14.81,"latestTime":"19:34 EDT","volume":4077,"amount":60380.16,"timestamp":1784936051086,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.008855585831062723,"floatShares":23281000,"shares":34093745,"eps":-0.648931,"marketStatus":"Market Closed","change":0.13,"latestTime":"07-24 16:00:00 EDT","open":14.87,"high":15,"low":14.28,"amount":3946980.6872320003,"amplitude":0.049046,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.648931,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1619064000000,"exchange":"NASDAQ","adjPreClose":14.68,"preHourTrading":{"tag":"盘前","latestPrice":14.617,"preClose":14.68,"latestTime":"05:01 EDT","volume":1,"amount":14.617,"timestamp":1784883694670,"change":-0.063,"changeRate":-0.004292,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":14.81,"preClose":14.81,"latestTime":"19:34 EDT","volume":4077,"amount":60380.16,"timestamp":1784936051086,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3758708934095023,"impliedVol":0.7262,"impliedVolPercentile":0.6215},"requestUrl":"/m/hq/s/NPCE","defaultTab":"news","newsList":[{"id":"2653741579","title":"Neuropace Inc : Mizuho Initiates Coverage with Outperform Rating; Target Price $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2653741579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653741579?lang=en_us&edition=fundamental","pubTime":"2026-07-23 18:54","pubTimestamp":1784804051,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nFWN43P0UY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NPCE","BK4082","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642373244","title":"NeuroPace Shareholders Approve Directors and Auditor at Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642373244","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642373244?lang=en_us&edition=fundamental","pubTime":"2026-06-09 06:26","pubTimestamp":1780957619,"startTime":"0","endTime":"0","summary":"NeuroPace ( ($NPCE) ) has shared an update. On June 5, 2026, NeuroPace, Inc. held its 2026 Annual Meeting of Stockholders virtually, where sharehol...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuropace-shareholders-approve-directors-and-auditor-at-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuropace-shareholders-approve-directors-and-auditor-at-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE","BK4082","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642434930","title":"NeuroPace shareholders elect directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642434930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642434930?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:55","pubTimestamp":1780952106,"startTime":"0","endTime":"0","summary":"Neuropace held its 2026 annual shareholder meeting on June 5, 2026.Shareholders selected Lisa Andrade, Scott Huennekens as Class II directors with terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL72FNNn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE","BK4082","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639222056","title":"NeuroPace attends ASSFN meeting, spotlights expanding role of responsive neuromodulation in epilepsy care","url":"https://stock-news.laohu8.com/highlight/detail?id=2639222056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639222056?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:06","pubTimestamp":1780056409,"startTime":"0","endTime":"0","summary":"NeuroPace will attend the ASSFN Meeting in Cleveland, Ohio, running May 29–June 2, 2026.Company plans to highlight long-term RNS System outcomes, NAUTILUS results in idiopathic generalized epilepsy, supported by data-driven clinical tools.A breakfast symposium on thalamic neuromodulation is scheduled for June 1, 2026, 7:00 a.m. ET.NeuroPace will support an epilepsy surgery education course on May 30, 2026, 8:30 a.m.–12:00 p.m. ET.Booth demonstrations and physician feedback sessions are planned throughout the meeting, including a preview of the FDA-cleared ECoG Assistant tool.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire  on May 29, 2026, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDLKz1nF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4082","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639221096","title":"NeuroPace wins FDA approval for ECoG Assistant AI epilepsy feature","url":"https://stock-news.laohu8.com/highlight/detail?id=2639221096","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639221096?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:01","pubTimestamp":1780056103,"startTime":"0","endTime":"0","summary":"NeuroPace won FDA clearance for ECoG Assistant, an AI feature to speed clinician review of intracranial EEG data for its RNS System.The model was trained on 124,450 epileptologist-labeled iEEG long-episode records, aiming to support faster treatment decisions.NeuroPace also filed its next-generation cloud-based PDMS for FDA review, targeting approval in Q2 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL90plZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4082","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639186622","title":"Neuropace Announces FDA Approval of Ecog Assistant™, Advancing AI-Driven Epilepsy Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2639186622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639186622?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:00","pubTimestamp":1780056000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nTUARNGJG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NPCE","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638505093","title":"Analysts Conflicted on These Healthcare Names: NeoGenomics (NEO) and NeuroPace (NPCE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638505093","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638505093?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:40","pubTimestamp":1779874808,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on NeoGenomics (NEO) and NeuroPace (NPCE). NeoGenomics (NEO) William...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-neogenomics-neo-and-neuropace-npce-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-neogenomics-neo-and-neuropace-npce-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4588","LU0029874061.USD","LU0106261612.USD","XLV","LABU","BK4581","XBI","NPCE","NEO","BK4121","LU0128526141.USD","BK4082","BK4196","BK4137","BK4585","LU0012050646.USD","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635198034","title":"NeuroPace price target raised to $20 from $19 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2635198034","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635198034?lang=en_us&edition=fundamental","pubTime":"2026-05-16 02:24","pubTimestamp":1778869446,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on NeuroPace (NPCE) to $20 from $19 and keeps a Buy rating on the shares following quarterly results...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neuropace-price-target-raised-to-20-from-19-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neuropace-price-target-raised-to-20-from-19-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635031434","title":"NeuroPace Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2635031434","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635031434?lang=en_us&edition=fundamental","pubTime":"2026-05-16 01:45","pubTimestamp":1778867100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NPCE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 13:45 ET (17:45 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635757992","title":"NeuroPace Earnings Call Highlights RNS Growth Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2635757992","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635757992?lang=en_us&edition=fundamental","pubTime":"2026-05-14 08:14","pubTimestamp":1778717691,"startTime":"0","endTime":"0","summary":"Neuropace, Inc. (($NPCE)) has held its Q1 earnings call. Read on for the main highlights of the call. NeuroPace’s latest earnings call struck an up...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neuropace-earnings-call-highlights-rns-growth-momentum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neuropace-earnings-call-highlights-rns-growth-momentum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780636","title":"NeuroPace (NPCE) Receives a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780636?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:16","pubTimestamp":1778678202,"startTime":"0","endTime":"0","summary":"In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on NeuroPace, with a price target of $20.00. Takkinen covers th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neuropace-npce-receives-a-buy-from-lake-street-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neuropace-npce-receives-a-buy-from-lake-street-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635555781","title":"NeuroPace: Buy Rating Reiterated on Raised Guidance, Differentiated RNS Platform, and Attractive $20 Price Target Versus High-Growth Med-Tech Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2635555781","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635555781?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:36","pubTimestamp":1778672165,"startTime":"0","endTime":"0","summary":"Rohin K Patel, an analyst from J.P. Morgan, maintained the Buy rating on NeuroPace. The associated price target is $20.00. Rohin K Patel has given ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/neuropace-buy-rating-reiterated-on-raised-guidance-differentiated-rns-platform-and-attractive-20-price-target-versus-high-growth-med-tech-peers-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/neuropace-buy-rating-reiterated-on-raised-guidance-differentiated-rns-platform-and-attractive-20-price-target-versus-high-growth-med-tech-peers-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635422381","title":"Neuropace Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635422381","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635422381?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:01","pubTimestamp":1778619708,"startTime":"0","endTime":"0","summary":"Neuropace Inc reports results for the quarter ended March 31 - Earnings SummaryNeuropace Inc NPCE.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter ended March 31, higher tha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P377:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","NPCE","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635288642","title":"NeuroPace Q1 Loss Narrows, Revenue Declines","url":"https://stock-news.laohu8.com/highlight/detail?id=2635288642","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635288642?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:32","pubTimestamp":1778617971,"startTime":"0","endTime":"0","summary":"NeuroPace  reported a Q1 loss late Tuesday of $0.20 per diluted share, narrowing from a loss of $0.21 a year earlier.Analysts surveyed by FactSet expected a loss of $0.23.Revenue for the three months ended March 31 was $22.1 million, down from $22.5 million a year earlier.Analysts polled by FactSet expected $21.6 million.For the full-year 2026, the company now expects revenue of $99 million to $101 million from $98 million to $100 million previously. Analysts expect $98.9 million.Shares of NeuroPace were up 2.2% in after-hours trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635403602","title":"NeuroPace Q1 revenue rises 20%, beats estimates, raises 2026 outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2635403602","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635403602?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:18","pubTimestamp":1778617133,"startTime":"0","endTime":"0","summary":"NeuroPace Q1 revenue rises 20%, beats estimates, raises 2026 outlookOverviewU.S. epilepsy device maker's Q1 revenue rose 20% yr/yr, beating analyst expectationsCompany raised 2026 revenue guidance to ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P1DP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE","BK4082","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635476922","title":"NeuroPace Q1 EPS $(0.20) Beats $(0.23) Estimate, Sales $22.068M Beat $21.644M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635476922","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635476922?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:06","pubTimestamp":1778616397,"startTime":"0","endTime":"0","summary":"NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.23) by 13.04 percent. This is a 4.76 percent increase over losses of $(0.21) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52505572/neuropace-q1-eps-0-20-beats-0-23-estimate-sales-22-068m-beat-21-644m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NeuroPace Q1 EPS $(0.20) Beats $(0.23) Estimate, Sales $22.068M Beat $21.644M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247675","title":"NeuroPace Q1 net loss widens to $6.7 million; revenue rises 20.1% to $22 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247675","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247675?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:06","pubTimestamp":1778616383,"startTime":"0","endTime":"0","summary":"Neuropace posted first-quarter revenue of $22.1 million, with RNS System revenue rising 19.5% year over year to $21.7 million.GAAP net loss widened to $6.7 million, or $0.20 per share.Non-GAAP gross margin slipped 1.1 percentage points to 82.5%.FDA mid-cycle review meeting for NAUTILUS PMA supplement completed, with active prescribers, accounts, and patient pipeline reaching new all-time highs.Full-year revenue guidance raised to $99 million-$101 million; adjusted EBITDA loss outlook improved to $8.5 million-$9.5 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief via Business Wire  on May 12, 2026, and is solely responsible for the information contained","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLc4dxpC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247945","title":"BRIEF-NeuroPace, Inc. Q1 EPS USD -0.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247945","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247945?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616346,"startTime":"0","endTime":"0","summary":"BRIEF-NeuroPace, Inc. Q1 EPS USD -0.2\n\n\nMay 12 (Reuters) - NeuroPace, Inc. Q1 revenue USD 22.068 million vs. IBES estimate USD 21.6 million.\n\nQ1 income from operations USD -5.568 million\nQ1 gross profit USD 18.048 million\nQ1 operating expenses USD 23.616 million\nQ1 net income USD -6.689 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLX02462A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247530","title":"Neuropace, Inc. Q1 EPS USD -0.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247530?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616302,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLX02462A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4539","NPCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247956","title":"Press Release: NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247956","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247956?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"-- Raises full year 2026 guidance to $99 million to $101 million, up from $98 million to $100 million previously--. --Assumes 21% to 23% growth in core RNS revenue from existing indications, excluding any contribution from idiopathic generalized epilepsy  indication expansion--. --Continues to expect IGE contribution following potential NAUTILUS PMA-Supplement  approval in mid-2026--. NeuroPace, Inc. , a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.--  Total revenue of $22.1 million in the quarter. Excluding DIXI Medical,total revenue of $22.0 million representing 20.1% year over year growth. --  GAAP net loss in the first quarter of 2026 was  million compared. first quarter of 2026, an improvement of $0.8 million compared to a loss. Beginning this quarter, the Company reports gross margin and operating expenses on a non-GAAP basis, ex","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NPCE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neuropace.com;investors.neuropace.com","stockEarnings":[{"period":"1week","weight":-0.079},{"period":"1month","weight":-0.0869},{"period":"3month","weight":-0.1185},{"period":"6month","weight":-0.1137},{"period":"1year","weight":0.6329},{"period":"ytd","weight":-0.0408}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.513635},{"month":2,"riseRate":0.4,"avgChangeRate":0.014939},{"month":3,"riseRate":0.2,"avgChangeRate":-0.075134},{"month":4,"riseRate":0.4,"avgChangeRate":0.054856},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.123698},{"month":6,"riseRate":0.5,"avgChangeRate":-0.043589},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.046353},{"month":8,"riseRate":0.6,"avgChangeRate":0.216975},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065676},{"month":10,"riseRate":0,"avgChangeRate":-0.132059},{"month":11,"riseRate":0.6,"avgChangeRate":0.163487},{"month":12,"riseRate":0.6,"avgChangeRate":0.015944}],"exchange":"NASDAQ","name":"NeuroPace Inc.","nameEN":"NeuroPace Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NeuroPace Inc.,NPCE,NeuroPace Inc.股票,NeuroPace Inc.股票老虎,NeuroPace Inc.股票老虎国际,NeuroPace Inc.行情,NeuroPace Inc.股票行情,NeuroPace Inc.股价,NeuroPace Inc.股市,NeuroPace Inc.股票价格,NeuroPace Inc.股票交易,NeuroPace Inc.股票购买,NeuroPace Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NeuroPace Inc.(NPCE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NeuroPace Inc.(NPCE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}